Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon
This article was originally published in The Pink Sheet Daily
Executive Summary
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
You may also be interested in...
Oxytrol Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant
Merck’s proposed Rx-to-OTC switch of Oxytrol for Women is about identifying symptoms of overactive bladder, not diagnosing the condition, says Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee. Several NDAC members Nov. 9 insisted OAB should be diagnosed before treatment.
Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales
A 14% decline in nutritional segment sales that slightly hampered Perrigo Co.’s consumer business revenue could affect the firm’s stock valuation if it cannot turn the division around, multiple analysts said. But Perrigo says the dip was expected and temporary,
Nexium OTC Switch Would Face Crowded Field, Potential Questions
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.